[go: up one dir, main page]

NO20000771D0 - Anvendelse av fankinon for behandling av Alzheimers sykdom - Google Patents

Anvendelse av fankinon for behandling av Alzheimers sykdom

Info

Publication number
NO20000771D0
NO20000771D0 NO20000771A NO20000771A NO20000771D0 NO 20000771 D0 NO20000771 D0 NO 20000771D0 NO 20000771 A NO20000771 A NO 20000771A NO 20000771 A NO20000771 A NO 20000771A NO 20000771 D0 NO20000771 D0 NO 20000771D0
Authority
NO
Norway
Prior art keywords
alzheimer
disease
treatment
fanquinone
prevention
Prior art date
Application number
NO20000771A
Other languages
English (en)
Other versions
NO317770B1 (no
NO20000771L (no
Inventor
Michel Xilinas
Panayotis Nikolas Gerolymatos
Original Assignee
P N Gerolymatos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by P N Gerolymatos Sa filed Critical P N Gerolymatos Sa
Publication of NO20000771D0 publication Critical patent/NO20000771D0/no
Publication of NO20000771L publication Critical patent/NO20000771L/no
Publication of NO317770B1 publication Critical patent/NO317770B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO20000771A 1997-08-21 2000-02-16 Anvendelse av fankinon for behandling av Alzheimers sykdom NO317770B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR97100330 1997-08-21
GR97100507 1997-12-31
PCT/IB1998/001095 WO1999009981A1 (en) 1997-08-21 1998-07-17 Use of phanquinone for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
NO20000771D0 true NO20000771D0 (no) 2000-02-16
NO20000771L NO20000771L (no) 2000-04-25
NO317770B1 NO317770B1 (no) 2004-12-13

Family

ID=26316681

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000771A NO317770B1 (no) 1997-08-21 2000-02-16 Anvendelse av fankinon for behandling av Alzheimers sykdom

Country Status (25)

Country Link
US (2) US6670369B1 (no)
EP (1) EP1007040B1 (no)
JP (1) JP2001513558A (no)
CN (1) CN1145482C (no)
AT (1) ATE217191T1 (no)
AU (1) AU741782B2 (no)
BG (1) BG64300B1 (no)
BR (1) BR9814945A (no)
CA (1) CA2301706C (no)
CZ (1) CZ299739B6 (no)
DE (1) DE69805305T2 (no)
DK (1) DK1007040T3 (no)
EA (1) EA002526B1 (no)
ES (1) ES2177024T3 (no)
HK (1) HK1029937A1 (no)
HU (1) HUP0004331A3 (no)
IL (1) IL134263A (no)
IS (1) IS1910B (no)
NO (1) NO317770B1 (no)
NZ (1) NZ502565A (no)
PL (1) PL191208B1 (no)
PT (1) PT1007040E (no)
SK (1) SK284708B6 (no)
TR (1) TR200000455T2 (no)
WO (1) WO1999009981A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
AR022215A1 (es) * 1999-01-07 2002-09-04 Gerolymatos P N Sa Utilizacion de la fanquinona para el tratamiento o prevencion del deterioro de la memoria
AU2001250573A1 (en) * 2000-04-28 2001-11-12 Michel Xilinas Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
EP1311299A4 (en) 2000-08-18 2008-01-02 Gen Hospital Corp METHOD OF IDENTIFICATION AND USE OF SUBSTANCES WHICH CATEGORIZE OR PROMOTE CATARACTA
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1602286B1 (en) * 2003-03-11 2009-10-28 Kaneka Corporation Oil-in-water type emulsion containing coenzyme q10 and process for producing the same
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
SI3137093T1 (en) * 2014-04-29 2018-01-31 Affiris Ag Treatment and prevention of Alzheimer's disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE1804736A1 (de) 1967-11-02 1969-06-26 Ciba Geigy Pharmazeutisches Praeparat
IL40311A (en) 1972-09-06 1973-04-30 Pharmaplantex Ltd Pharmaceutical preparation for the treatment of gastro-intestinal troubles containing phanquone and furazolidone
GB1472257A (en) * 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4981844A (en) * 1988-10-04 1991-01-01 University Of Cincinnati Method to improve immune response and resistance to infection following surgery by diet composition
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
CA2123211C (en) 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
GB9126874D0 (en) * 1991-12-18 1992-02-19 Wellcome Found Medicaments
EP0713392A1 (en) * 1994-05-11 1996-05-29 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
CZ292411B6 (cs) 1996-08-13 2003-09-17 P. N. Gerolymatos S. A. Farmaceutický prostředek
CA2284170C (en) 1997-03-11 2008-12-02 The General Hospital Corporation Identification of agents for use in the treatment of alzheimer's disease
US5980882A (en) 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
AR022215A1 (es) 1999-01-07 2002-09-04 Gerolymatos P N Sa Utilizacion de la fanquinona para el tratamiento o prevencion del deterioro de la memoria
AU2001250573A1 (en) 2000-04-28 2001-11-12 Michel Xilinas Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AU2001250571A1 (en) 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol

Also Published As

Publication number Publication date
NO317770B1 (no) 2004-12-13
US7629354B2 (en) 2009-12-08
HUP0004331A3 (en) 2001-09-28
PT1007040E (pt) 2002-10-31
DE69805305D1 (de) 2002-06-13
CZ299739B6 (cs) 2008-11-05
IS5366A (is) 2000-01-28
US20050003018A1 (en) 2005-01-06
PL338673A1 (en) 2000-11-20
TR200000455T2 (tr) 2000-09-21
CA2301706C (en) 2005-10-04
PL191208B1 (pl) 2006-03-31
CZ2000611A3 (cs) 2000-08-16
US6670369B1 (en) 2003-12-30
DK1007040T3 (da) 2002-08-26
BG104179A (en) 2000-10-31
IL134263A0 (en) 2001-04-30
EP1007040A1 (en) 2000-06-14
WO1999009981A1 (en) 1999-03-04
SK284708B6 (sk) 2005-09-08
HK1029937A1 (en) 2001-04-20
EA200000242A1 (ru) 2000-08-28
NO20000771L (no) 2000-04-25
DE69805305T2 (de) 2002-12-05
IL134263A (en) 2006-04-10
IS1910B (is) 2003-12-31
EP1007040B1 (en) 2002-05-08
BG64300B1 (bg) 2004-09-30
SK2062000A3 (en) 2000-08-14
ES2177024T3 (es) 2002-12-01
NZ502565A (en) 2002-03-01
CA2301706A1 (en) 1999-03-04
HUP0004331A2 (hu) 2001-05-28
BR9814945A (pt) 2000-09-05
ATE217191T1 (de) 2002-05-15
EA002526B1 (ru) 2002-06-27
AU8124198A (en) 1999-03-16
CN1145482C (zh) 2004-04-14
CN1267218A (zh) 2000-09-20
AU741782B2 (en) 2001-12-06
JP2001513558A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
FI962557A0 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
HUP0103654A2 (hu) Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására
NO20026199L (no) Forbindelser for behandling av Alzheimers sykdom
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FI982689L (fi) 2-fenyyli-1,2-bentsoisoselenatsol-3(2H)-onin käyttö Alzheimerin taudin käsittelyyn tarkoiettujen farmaseuttisten valmisteiden valmistukseen
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
BR0012921A (pt) Compostos calcilìticos
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
NO953072L (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
RS49595B (sr) Primena 2-fenil-1,2- benzizoselenazol-3(2h)-ona za izradu farmaceutskog preparata za lečenje alchajmerove bolesti
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees